Literature DB >> 19514099

The changes of aggregability of blood platelets in schizophrenia.

Anna Dietrich-Muszalska1, Beata Olas.   

Abstract

OBJECTIVE: Oxidative stress in schizophrenia may be responsible for the changes of platelet function and reactivity. Therefore, the aim of our present study was to evaluate the response of platelets from patients with schizophrenia to platelet agonists such as ADP and collagen.
RESULTS: Platelet aggregation of schizophrenic patients and healthy subjects stimulated by collagen or ADP showed significant differences. Aggregation of platelets stimulated by collagen was significantly lower in schizophrenic patients (about 86%) than in healthy subjects (P=0.022), but when this process was induced by ADP, aggregation of platelets was significantly higher in schizophrenic patients (increase to about 112%) than in healthy subjects (P=0.018). We also observed that antipsychotic drugs (clozapine, risperidone, olanzapine, haloperidol) reduce aggregation of platelets of schizophrenic patients and healthy group in vitro.
CONCLUSION: The obtained results indicate that the response of platelets from schizophrenic patients to ADP and collagen is different than in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514099     DOI: 10.1080/15622970701557993

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  13 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

2.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

3.  Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.

Authors:  Bradley J Smith; Victor C Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 4.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

5.  Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen.

Authors:  Wei-Lien Tseng; Chien-Ling Huang; Kowit-Yu Chong; Chang-Huei Liao; Arnold Stern; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Cell Mol Life Sci       Date:  2009-11-21       Impact factor: 9.261

6.  The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors.

Authors:  Angelika Schedel; Patrick Schloss; Harald Klüter; Peter Bugert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-10       Impact factor: 3.000

7.  Platelets in psychiatric disorders.

Authors:  Daniela Ehrlich; Christian Humpel
Journal:  World J Psychiatry       Date:  2012-12-22

8.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

9.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

10.  Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: A preliminary study.

Authors:  Murat Semiz; Hasan Yücel; Onder Kavakçı; Osman Yıldırım; Ali Zorlu; Mehmet Birhan Yılmaz; Zekeriya Küçükdurmaz; Fatih Canan
Journal:  J Res Med Sci       Date:  2013-07       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.